Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2016-001499-31
    Sponsor's Protocol Code Number:Epi-RCHOP
    National Competent Authority:Belgium - FPS Health-DGM
    Clinical Trial Type:EEA CTA
    Trial Status:Trial now transitioned
    Date on which this record was first entered in the EudraCT database:2020-04-15
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedBelgium - FPS Health-DGM
    A.2EudraCT number2016-001499-31
    A.3Full title of the trial
    A Phase Ib-II Study of tazemetostat (EPZ-6438) in newly diagnosed Diffuse Large B Cell Lymphoma (DLBCL) or high risk Follicular Lymphoma (FL) patients treated by R-CHOP
    Etude de phase Ib-II du tazemetostat (EPZ-6438) chez des patients atteints de lymphome diffus à grandes cellules B (DLBCL) ou de lymphome folliculaire de risque élevé (LF) traités par R-CHOP
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Study of tazemetostat in newly diagnosed Diffuse Large B Cell Lymphoma (DLBCL) patients or high risk Follicular Lymphoma (FL) patientstreated by R-CHOP
    Etude du tazemetostat chez des patients atteints de lymphome diffus à grandes cellules B (DLBCL) ou de lymphome folliculaire de risque élevé (LF) traités par R-CHOP traités par R-CHOP
    A.4.1Sponsor's protocol code numberEpi-RCHOP
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorLYSARC
    B.1.3.4CountryFrance
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportEpizyme
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationLYSARC
    B.5.2Functional name of contact pointProject Manager
    B.5.3 Address:
    B.5.3.1Street AddressCH Lyon Sud - Bâtiment 2D
    B.5.3.2Town/ cityPierre Bénite Cedex
    B.5.3.3Post code69495
    B.5.3.4CountryFrance
    B.5.4Telephone number0033472 66 93 33
    B.5.5Fax number00334 26 07 40 55
    B.5.6E-mailEpi-RCHOP@lysarc.org
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nametazemetostat
    D.3.2Product code EPZ-6438
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNTAZEMETOSTAT
    D.3.9.1CAS number 1467052-75-0
    D.3.9.2Current sponsor codeEPZ-6438
    D.3.9.4EV Substance CodeSUB178719
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number200
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    newly diagnosed Diffuse Large B Cell Lymphoma (DLBCL) or high risk Follicular Lymphoma (FL)
    Lymphome B Diffus à Grande Cellule (DLBCL) ou de lymphome folliculaire de risque élevé (LF)
    E.1.1.1Medical condition in easily understood language
    Diffuse Large B Cell Lymphoma (DLBCL) or high risk Follicular Lymphoma (FL)
    Lymphome B Diffus à Grande Cellule (DLBCL) ou de lymphome folliculaire de risque élevé (LF)
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level HLT
    E.1.2Classification code 10012819
    E.1.2Term Diffuse large B-cell lymphomas
    E.1.2System Organ Class 100000004851
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 24.0
    E.1.2Level LLT
    E.1.2Classification code 10029473
    E.1.2Term Nodular (follicular) lymphoma
    E.1.2System Organ Class 100000004864
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Phase Ib: to determine the recommended phase II dose (RP2D) for tazemetostat in patients treated with R-CHOP 21

    Phase II – DLBCL cohort:
    • to determine the Complete Response Rate (CRR) based on local assessment according to Cheson IWG 2014: Lugano Classification (i.e. categories 1- 3 on the 5 point Deauville scale) at the end of treatment or at permanent treatment discontinuation.End of treatment is defined as after 6 cycles of Epi-RCHOP 21 + 2 cycles of Tazemetostat and Rituximab.
    Phase II – FL cohort:
    • to determine the Complete Response Rate (CRR) based on local assessment at the end of induction or at permanent treatment discontinuation according to Cheson IWG 2014: Lugano Classification (i.e. Deauville scale 1-3). End of induction is defined as after 6 cycles of Epi-RCHOP 21 + 2 cycles of Tazemetostat and Rituximab.
    Phase Ib: déterminer la dose recommandée de phase II (RP2D) dutazemetostat chez les patients traités par R-CHOP 21

    Phase II – cohorte DLBCL :
    • Déterminer le taux de réponse complète basée sur l’évaluation locale selon Cheson 2014 (classification de Lugano (i.e. échelle de Deauville 1 à 3) en fin de traitement ou bien à l’arrêt définitif du traitement. La fin de traitement est définie après 6 cycles d’Epi-RCHOP + 2 cycles de Tazemetostat et Rituximab

    Phase II – cohorte FL :
    • Déterminer le taux de réponse complète basée sur l’évaluation locale selon Cheson 2014 (classification de Lugano (i.e. échelle de Deauville 1 à 3) en fin d’induction ou bien à l’arrêt définitif du traitement. La fin d’induction est définie après 6 cycles d’Epi-RCHOP + 2 cycles de Tazemetostat et Rituximab
    E.2.2Secondary objectives of the trial
    Phase Ib:
    - to assess the pharmacokinetics of the CHOP 21 components +/- tazemetostat
    - to assess the pharmacokinetics of tazemetostat and its metabolite, EPZ-6930 + R-CHOP 21
    - to evaluate the preliminary anti-tumor activity of tazemetostat using Cheson IWG 2014
    Phase II – DLBCL cohort:
    • To determine the safety of tazemetostat
    • To determine CRR by central review at the end of treatment
    • To evaluate the overall response rate and progression free survival at 52 and 104 w and overall
    • To evaluate duration of response and overall survival
    • To evaluate the Best Overall Response
    Phase II – FL cohort :
    • To determine the safety of tazemetostat
    • To determine PET EOI CRR rate
    • To determine the complete response rate and overall response rate at the end of rituximab maintenance
    • To evaluate progression free survival overall and at 24 months, event-free survival overall and at 24 months, and overall survival .
    • To evaluate duration of response
    • To evaluate BOR

    Phase Ib:
    • évaluer la pharmacocinétique des composants du CHOP 21 +/-tazemetostat
    • évaluer la pharmacocinétique du tazemetostat et de son métabolite, EPZ-6930 + R-CHOP 21
    • évaluer l'activité anti-tumorale préliminaire du tazemetostat selon Cheson IWG 2014
    Phase II– cohorte DLBCL:
    • Déterminer la tolérance du tazemetostat
    • Determiner le taux de réponse complète
    • Evaluer le taux de réponse globale et la survie sans progression
    • Evaluer la durée de la réponse et de la survie globale
    • Evaluer la meilleure réponse globale
    Phase II – cohorte LF:
    • Déterminer la tolérance du tazemetostat
    • Déterminer le taux de réponse complète à la fin de l’induction
    • Déterminer le taux de réponse complete et le taux de réponse globale à la fin de la maintenance par rituximab
    • Evaluer la survie sans progression globale et à 24 mois, la survie sans évènement globale et à 24 mois, et la survie globale
    • Evaluer la durée de la reponse
    • Evaluer la meilleure réponse globale
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    ___Cohort DLBCL : 1. Patients with an untreated DLBCL de novo or transformed from indolent lymphoma (CD 20 positive) Or CD20+ Follicular lymphoma grade 3B with
    - Phase Ib aaIPI ≥ 2
    - Phase II: aaIPI ≥ 1
    2. Age between 60 and 80 years included

    ____Cohort FOLLICULAR :
    1. High Tumor Burden (at least one GELF criteria except isolated elevated LDH at baseline) frontline follicular lymphoma (FL) with high risk FLIPI 3-5
    2.Aged between 18 years and 80 years included
    11 bis. Females of childbearing potential (FCBP) must agree to use one reliable form of contraception or to practice complete abstinence from heterosexual contact during the following time periods related to this study: 1) for at least 28 days before starting study drug; 2) while participating in the study; 3) dose interruptions; and 4) for at least 12 months after discontinuation of any study treatment (R-CHOP, tazemetostat, Rituximab)

    ____Both cohorts DLBCL and Follicular :
    1bis. For phase II patients: Bi-dimensionally measurable disease defined by at least one single node or tumor lesion > 1.5 cm assessed by CT scan and/or clinical examination AND a FDG avid disease by PETscan
    3. ECOG performance status of 0, 1 or 2 (0 or 1 only for phase Ib)
    4. Signed informed consent
    5. Life expectancy of ≥ 90 days (3 months) before starting tazemetostat
    6. Adequate renal function as calculated by a creatinine clearance > 40 mL/min by local institutional formula
    7. Adequate bone marrow function as defined as:
    - ANC ≥ 1500/mm3 (≥ 1.5 X 109/L)
    - Platelets ≥ 75,000/mm3 (≥ 75 X 109/L) without platelet transfusion dependency during the last 7 days
    -Hemoglobin ≥ 9 g/dL (may receive transfusion)
    8. Adequate liver function as defined as:
    - Total bilirubin ≤ 1.5 × the upper limit of normal (ULN) except for unconjugated hyperbilirubinemia of Gilbert’s syndrome
    - Alkaline phosphatase (in absence of bone disease), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 X ULN (or ≤ 5 X ULN if related to lymphoma involvement)
    -Patients with prior Hepatitis B and C are eligible if, for Hepatitis B detection, surface antigen is negative and/or HBV DNA is undetectable, and for Hepatitis C detection, if HCV RNA is undetectable.
    - 9. Left ventricular ejection fraction (LVEF) > 50% of echocardiography or multiple gated acquisition (MUGA) scan
    - 10. Adequate tissue (surgical excision is recommended) for central pathology review and biological caracterisation
    11. Males with partners of childbearing potential must agree to use
    reliable forms of contraception during 12 months after last treatment
    administration
    12. Patient covered by any social security system (for France only)
    13. Patient who understands and speaks one of the country official languages
    ___Cohorte DLBCL: 1. Patients atteints d’un lymphome diffus à grandes cellules B au diagnostic ou issu de la transformation d’un lymphome indolent (CD 20 positif) ou Lymphome folliculaire de grade 3b CD 20 positif avec
    - Phase Ib aaIPI ≥ 2
    - Phase II: aaIPI ≥ 1
    2. Age compris entre 60 et 80 ans inclus

    ____Cohorte Folliculaire
    1. Patient atteint d’un lymphome folliculaire à forte masse tumorale (défini par au moins un critère du GELF, un taux de LDH sérique élevée à la baseline ne peut pas être utilisé comme seul critère) et avec un FLIPI élevé 3 à 5, et requérant une 1ère ligne de traitement
    2. Age compris entre 18 et 80 ans inclus
    11 bis. Les femmes en âge de procréer doivent accepter d’utiliser une forme de contraception acceptable ou de pratiquer une abstinence hétérosexuelle complète pendant les périodes suivantes relatives à l’étude : 1) au moins 28 jours avant le début du traitement expérimental, 2) pendant toute la participation à l’étude, 3) les interruptions de dose, 4) au moins 12 mois après l’arrêt de n’importe quel traitement de l’étude (R-CHOP, tazemetostat ou rituximab)

    ___Les 2 cohortes (DLBCL et folliculaire)
    1bis. Pour les patients de la phase II: maladie bi-dimensionnelle mesurable définie par au moins un nodule ou une lésion tumorale > 1.5 cm évaluée par CT scan et/ou l’examen clinique ET une maladie « avide » de FDG au PETscan
    3. ECOG (performance status) de 0, 1 ou 2 (0 ou 1 uniquement pour la phase I)
    4. Consentement libre et éclairé signé
    5. Espérance de vie ≥ 90 jours (3 mois) avant le début de traitement par tazemetostat
    6. Fonction rénale adéquate, établie par le calcul local d’une clairance à la créatinine > 40 mL/min
    7. Fonction médullaire adéquate telle que définie par:
    - Neutrophiles ≥ 1500/mm3 (≥ 1,5 X 109/L)
    - Plaquettes ≥ 75,000/mm3 (≥ 75 X 109/L) sans support transfusionnel durant les 7 jours précédents
    - Hémoglobine ≥ 9 g/dL (support transfusionnel possible)
    8. Fonction hépatique adéquate telle que définie par:
    - Bilirubine totale ≤ 1.5 X la normale supérieure, sauf en cas d’hyper bilirubinémie non conjuguée due à un syndrome de Gilbert’
    - Phosphatase alcaline (en l’absence de maladie osseuse), alanine aminotransferase (ALT) et aspartate aminotransferase (AST)
    ≤ 3 X la normale supérieure, (ou ≤ 5 X la normale supérieure si lié à l’atteinte du lymphome)
    - Les patients avec des antécédents d’hépatites B et C sont incluables, si, pour la détection de l’hépatite B, l’antigène de surface est négatif et /ou l’ADN HBV est indétectable, et si, pour la détection de l’hépatite C, l’ARN HCV est indétectable
    9. Fraction d’éjection ventriculaire gauche (FEVG) > 50% à l’échocardiographie ou à la scintigraphie cardiaque (MUGA)
    10. Matériel tumoral suffisant (exérèse chirurgicale recommandée) pour revue pathologique centralisée et caractérisation biologique
    11. Les patients masculins avec des partenaires en âge de procréer doivent accepter d’utiliser des méthodes fiables de contraception pendant les 12 mois suivants la dernière administration de traitement
    12. Patient couvert par un système de sécurité sociale (pour la France uniquement)
    13. Patient qui comprend et parle une des langues officielles du pays
    E.4Principal exclusion criteria
    ___Both cohorts:
    1. Central nervous system or meningeal involvement
    2. Contraindication to any drug contained in the chemotherapy regimen
    3. Prior treatment with tazemetostat or other inhibitor of EZH2
    4. Patients who are undergoing active treatment for another malignancy, exceptions include: A patient who has been disease free for 2 years, or a patient with a history of a completely resected non-melanoma skin cancer or successfully treated in situ carcinoma is eligible
    Patients with prior history of myeloid malignancies, including myelodysplastic syndrome (MDS) or Acute Myeloid Leukemia(AML)or prior history of T-LBL/T-ALL are excluded whatever receiving treatment or not and whatever date of diagnosis of these pathologies
    5. Patients taking medications that are known potent CYP3A4 inducers/inhibitors (including St. John’s wort)
    6. Patients unwilling to exclude St. John’s wort, Seville oranges, grapefruit juice and/or grapefruit from diet
    7. Major surgery within 4 weeks before first dose of study drug (minor procedures including transcutaneous biopsy, central line placement are permitted within 2 weeks of enrollment)
    8. Inability to take oral medication or malabsorption syndrome or any other uncontrolled gastrointestinal condition that would impare ability to take tazemetostat
    9. Significant cardiovascular impairment: congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina, myocardial infarction or stroke within 6 months of first dose of tazemetostat or ventricular arrhythmia
    10. NOt applicable
    11. Active uncontrolled infection requiring systemic therapy
    12. Congenital immunodeficiency or known HIV (human immunodeficiency virus infection)
    13. Any other major illness, that in the investigator’s judgement, will substantially increase the risk associated with the patient’s participation in the study
    14. Patients who have undergone a solid organ transplant
    16. Treatment with any investigational drug or device within 30 days before planned first cycle of chemotherapy
    18. Person deprived of his/her liberty by a judicial or administrative decision
    19. Adult person under legal protection
    20. Person hospitalized without consent
    21. Adult person unabled to provide informed consent because of intellectual impairment, any serious medical condition, laboratory abnormality or psychiatric illness

    ___DLBCL cohort
    15. Previous treatment for B cell lymphoma, except glucocorticoids (no more than 7 days before inclusion, 1 mg/kg/day max)

    ___ Follicular cohort
    15. Prior therapy for lymphoma including radiotherapy except glucocorticoids (no more than 7 days before inclusion, 1mg/kg/day max)
    17. Pregnant or lactating females
    ___Les 2 cohortes (DLBCL et folliculaire) :
    1. Envahissement du système nerveux central ou des méninges
    2. Contre-indication à l’un des composants de l’immunochimiothérapie
    3. Patient ayant déjà reçu du tazemetostat ou tout autre inhibiteur d’EZH2
    4. Patients recevant un traitement actif pour toute autre tumeur maligne. Les patients en rémission depuis au moins 2 ans ou ayant un antécédent de cancer de la peau totalement réséqué (hors mélanome) ou de carcinome localisé traité localement avec succès sont éligibles.
    Les patients ayant des antécédents de tumeurs malignes myéloïdes, y compris le syndrome myélodysplasique (SMD) ou leucémie aigüe myéloïdeou des antécédents de T-LBL/T-ALL sont exclus quel que soit le traitement reçu ou non et quelle que soit la date du diagnostic de ces pathologies
    5. Patients prenant un traitement connu pour être potentiellement inducteur ou inhibiteur du CYP3A4 (dont le millepertuis)
    6. Patients refusant d’exclure le millepertuis, les oranges amères et le pamplemousse de leur régime alimentaire
    7. Chirurgie majeure dans les 4 semaines précédant le début du traitement (les procédures mineures dont les biopsies transcutanées, les poses de voie centrale sont autorisées pendant les 2 semaines précédant l’inclusion)
    8. Incapacité à prendre un traitement par voie orale ou syndrome de malabsorption ou tout autre désordre gastro-intestinal non contrôlé qui pourrait impacter la capacité à prendre le tazemetostat
    9. Désordre cardiovasculaire significatif: insuffisance cardiaque de grade supérieure à la classe II de la New York Heart Association (NYHA), angor instable, infarctus du myocarde ou accident vasculaire cérébral dans les 6 mois précédents la première dose de tazemetostat ou arythmie ventriculaire
    10. Infection active non contrôlée nécessitant un traitement systémique
    11. Immunodéficience congénitale ou VIH connu (infection par le virus de l’immunodéficience humaine)
    12. Toute autre maladie grave qui, selon le jugement de l'investigateur, augmenterait significativement les risques du patient en cas de participation à cette étude
    13. Patients avec un antécédent de transplantation d’un organe solide
    15. Traitement par un medicament ou dispositif experimental dans les 30 jours précédents le démarrage de la chimiothérapie
    17. Personne privée de liberté par décision judiciaire ou adminstrative
    18. Personne adulte sous protection légale
    19. Personne hospitalisée sans son consentement
    20. Personne adulte incapable de donner son consentement éclairé en raison d’une déficience intellectuelle, d’un problème médical grave, d’une anomalie de laboratoire ou d’une maladie psychiatrique

    ___ Cohorte DLBCL:
    14. Patient ayant déjà reçu un traitement pour le lymphome à cellules B, exceptédes glucocorticoïdes (pas plus de 7 jours avant inclusion, 1 mg/kg/jour max)

    ___Cohorte folliculaire:
    14. Thérapie précédente pour le lymphome y compris radiothérapie excepté des glucocorticoïdes (pas plus de 7 jours avant inclusion, 1 mg/kg/jour max)
    17. Femme enceinte ou allaitante
    E.5 End points
    E.5.1Primary end point(s)
    Phase I :
    - RP2D

    Phase II - DLBCL cohort
    - CRR

    Phase II - Follicular lymphoma cohort
    - CRR
    Phase I :
    - RP2D
    E.5.1.1Timepoint(s) of evaluation of this end point
    Phase I
    - RP2D = 2 cycles

    Phase II - DLBCL cohort
    - CRR : 6 cycles of Epi-RCHOP 21 + 2 cycles of Tazemetostat and Rituximab.
    Phase II - Follicular lymphoma cohort
    - CRR : 6 cycles of Epi-RCHOP 21 + 2 cycles of Tazemetostat and Rituximab.
    E.5.2Secondary end point(s)
    Phase I :
    - PK CHOP21 +/- tazemetostat
    - PK tazemetostat and EPZ-6930 + CHOP 21
    - CR

    Phase II
    - ORR
    - PFS
    - PK CHOP21 +/- tazemetostat
    - PK tazemetostat and EPZ-6930 + CHOP 21
    - OS
    E.5.2.1Timepoint(s) of evaluation of this end point
    Phase I
    - PK CHOP21 +/- tazemetostat = C1D1 and C2D1
    - PK tazemetostat and EPZ-6930 + CHOP 21 = C1D1 and C2D1
    - CR = 8 cycles

    Phase II
    - ORR = 52 and 104 days, end of study
    - PFS = 52 and 104 days, end of study
    - PK CHOP21 +/- tazemetostat = C1D1 and C2D1
    - PK tazemetostat and EPZ-6930 + CHOP 21 = C1D1 and C2D1
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) Yes
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other Yes
    E.7.1.3.1Other trial type description
    RP2D
    Dose pour la phase II
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned25
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA25
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLP
    Dernière visite du dernier patient
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years5
    E.8.9.1In the Member State concerned months
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years5
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 33
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 100
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state30
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 201
    F.4.2.2In the whole clinical trial 201
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    not different from the expected normal treatment of that condition
    pas différent de la prise en charge normale pour le traitement de cette pathologie
    G. Investigator Networks to be involved in the Trial
    G.4 Investigator Network to be involved in the Trial: 1
    G.4.1Name of Organisation LYSA
    G.4.3.4Network Country France
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2020-06-05
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2020-06-05
    P. End of Trial
    P.End of Trial StatusTrial now transitioned
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 10:51:23 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA